Lithium Chloride → 6-(4-chlorophenyl)-1-methyl-8-(pyrimidin-2-yl)-5,6-dihydro-4H-benzo[b][1,2,4]triazolo[4,3-d][1,4]diazepine

HRID 1485417노트

반응식

HRID 1485417 반응식
Br[C:2]1[CH:3]=[CH:4][C:5]2[N:11]3[C:12]([CH3:15])=[N:13][N:14]=[C:10]3[CH2:9][CH2:8][N:7]([C:16]3[CH:21]=[CH:20][C:19]([Cl:22])=[CH:18][CH:17]=3)[C:6]=2[CH:23]=1.C([Sn](CCCC)(CCCC)[C:29]1[N:34]=[CH:33][CH:32]=[CH:31][N:30]=1)CCC.[Cl-].[Li+]>C1C=CC(P(C2C=CC=CC=2)[C-]2C=CC=C2)=CC=1.C1C=CC(P(C2C=CC=CC=2)[C-]2C=CC=C2)=CC=1.Cl[Pd]Cl.[Fe+2].C1(C)C=CC=CC=1>[Cl:22][C:19]1[CH:20]=[CH:21][C:16]([N:7]2[CH2:8][CH2:9][C:10]3=[N:14][N:13]=[C:12]([CH3:15])[N:11]3[C:5]3[CH:4]=[CH:3][C:2]([C:29]4[N:34]=[CH:33][CH:32]=[CH:31][N:30]=4)=[CH:23][C:6]2=3)=[CH:17][CH:18]=1

참가 물질

6

반응물 3

HCID 433294Lithium ChlorideHCID 27632512-(Tributylstannyl)pyrimidineHCID 709789288-bromo-6-(4-chlorophenyl)-1-methyl-5,6-dihydro-4H-benzo[b][1,2,4]triazolo[4,3-d][1,4]diazepine2회

생성물 1

HCID 709793666-(4-chlorophenyl)-1-methyl-8-(pyrimidin-2-yl)-5,6-dihydro-4H-benzo[b][1,2,4]triazolo[4,3-d][1,4]diazepine수율 5.1%

시약·촉매·용매 2

HCID 178418228Bis(cyclopenta-1,4-dien-1-yl(diphenyl)phosphane);dichloropalladium;iron(2+)촉매HCID 1140Toluene용매

반응 조건

온도
100 °C

실험 절차

Into a 25 mL sealed-tube evacuated and brimmed with nitrogen, was charged with a mixture of 8-bromo-6-(4-chlorophenyl)-1-methyl-5,6-dihydro-4H-benzo[b][1,2,4]triazolo[4,3-d][1,4]diazepine (Compound 13; 40 mg, 0.10 mmol), 2-(tributylstannyl)pyrimidine (56.8 g, 0.15 mmol), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (7.2 mg, 0.01 mmol), lithium chloride (6.5 mg, 0.15 mmol) and toluene (2 mL). The mixture was heated for 12 hours at 100° C. The mixture was concentrated in vacuo, partitioned with ethyl acetate (10 mL) and water (5 mL). The organic layer was separated, washed with brine, dried over anhydrous sodium sulfate and concentrated to give a residue. The residue was purified by prep-HPLC (Phenomenex C18 (150 mm*21.2 mm*5 um), acetonitrile/water=1:100 (0.1% formic acid), flow rate: 30 mL/min) to yield 6-(4-chlorophenyl)-1-methyl-8-(pyrimidin-2-yl)-5,6-dihydro-4H-benzo[b][1,2,4]triazolo[4,3-d][1,4]diazepine as a white solid (2 mg, 5%).

후처리

  1. customInto a 25 mL sealed-tube evacuated
  2. concentrationThe mixture was concentrated in vacuo
  3. custompartitioned with ethyl acetate (10 mL) and water (5 mL)
  4. customThe organic layer was separated
  5. washwashed with brine
  6. dry with materialdried over anhydrous sodium sulfate
  7. concentrationconcentrated
  8. customto give a residue
  9. customThe residue was purified by prep-HPLC (Phenomenex C18 (150 mm*21.2 mm*5 um), acetonitrile/water=1:100 (0.1% formic acid), flow rate: 30 mL/min)

출처 및 근거

ORD 기록
ord-8e572b3ae34a481f89736e30505fdecc
출처 데이터셋
uspto-grants-2016_08
특허 번호
US09422292B2

반응 노트

불러오는 중…